Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.

NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators

TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.

METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help

NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product

COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors

INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
Novelstem International Corp. Stock Analysis NSTM
NovelStem International Corp. develops novel diagnostic technology that can predict patients resistance to chemotherapy allowing for cancer treatments and the potential to reduce resistance to chemotherapy. The company is headquartered in Boca Raton, Florida. The firm's primary assets are NewStem Ltd (NewStem) and NetCo Partners (NetCo). NewStem focuses on the development and commercialization of diagnostic technology that can predict patients’ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is principally focused on utilizing proprietary human Pluripotent Stem Cells (hPSCs) and Haploid human Pluripotent Stem Cells (HhPSCs) in the development of diagnostic and therapeutic products in oncology. Its NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs. NetCo is a media business interest which owns Net Force, a book publishing franchise.
Read More Novelstem International Corp (NSTM) Chart
Key Statistics of Novelstem International Corp (NSTM)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.01Volume
334.00P/E Ratio (TTM)
0.2752 Week Range
Market Cap
542.66KAvg. Volume
21.47KDividend Yield
-Financial Metrics & Statements of Novelstem International Corp (NSTM)
FAQ's for Novelstem International Corp (NSTM)
- According to Musaffa’s Shariah screening methodology, Novelstem International Corp (NSTM) is currently classified as NOT COVERED as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Novelstem International Corp using these criteria to determine its compliance status.
- Muslim investors may consider investing in Novelstem International Corp if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Novelstem International Corp by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Novelstem International Corp may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Novelstem International Corp on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.